Showing 301-310 of 1698 results for "".
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar
- Over $500,000 Awarded for ALS and Mitochondrial Myopathies Researchhttps://practicalneurology.com/news/over-500000-awarded-for-als-and-mitochondrial-myopathies-research/2470938/The Muscular Dystrophy Association (MDA; Chicago, IL) has partnered with the French Muscular Dystrophy Association (AFM-Téléthon; Evry, France) to award a total of $510,000 in grant funding across 2 research projects. The grant funding is intended to accelerate the development of tr
- Muscular Dystrophy Association Launches Initiative to Support the Development of Treatments for Ultra-Rare Neuromuscular Diseaseshttps://practicalneurology.com/news/muscular-dystrophy-association-launches-initiative-to-support-the-development-of-treatments-for-ultra-rare-neuromuscular-diseases/2470571/The Muscular Dystrophy Association (MDA) announced the launch of the MDA Kickstart Program, an initiative to advance the development of treatments for ultra-rare neuromuscular diseases. The first project under the MDA Kickstart Program will focus on the development of a gene therapy for a rare fo
- Muscular Dystrophy Association Applauds Landmark Proposal on Accessible Air Travelhttps://practicalneurology.com/news/muscular-dystrophy-association-applauds-landmark-proposal-on-accessible-air-travel/2470417/The Muscular Dystrophy Association (MDA) celebrates a significant milestone in air travel accessibility for individuals with disabilities related to a proposal aimed at enhancing the safety, rights, and dignity of air travelers with disabilities made by the Biden Administration and the US Departm
- Muscular Dystrophy Association Announces the Start of 30 Days of Strength Campaignhttps://practicalneurology.com/news/mda-announces-the-start-of-30-days-of-strength-campaign/2470289/The Muscular Dystrophy Association (MDA) has announced the start of its 30 Days of Strength campaign for September, which is National Muscular Dystrophy Awareness Month. Throughout the month, the MDA will collaborate with influencers and community leaders, including Nyheim Hines, running back for
- VA Will Cover Lecanemab for Alzheimer Diseasehttps://practicalneurology.com/news/va-will-cover-lecanemab-for-alzheimer-disease/2470141/The Veterans Health Administration (VHA)—the division of the US D
- Ribitol Decreased Muscle Breakdown and Improved Function in Limb-Girdle Muscular Dystrophyhttps://practicalneurology.com/news/ribitol-decreased-muscle-breakdown-and-improved-function-in-limb-girdle-muscular-dystrophy/2470048/In a phase 2 study, individuals treated with ribitol (BBP-418; BridgeBio Pharma, Palo Alto, CA) for limb girdle muscular dystrophy type 2i (LGMD2i) for 12 months had a mean 75% reduction in creatine kinase (CK) levels—a marker of muscle degeneration. A mean 0.95-point improvement from basel
- Price of Aducanumab Treatment for Early Alzheimer Disease Cut in Halfhttps://practicalneurology.com/news/price-of-aducanumab-treatment-for-early-alzheimer-disease-cut-in-half/2469783/The price of the first potentially disease-modifying treatment for Alzheimer disease (AD), aducanumab (Aduhelm; Biogen, Cambridge, MA and Eisai, Woodcliff Lake, NJ), has been reduced by 50%—from $56,000 to $28,000 annually. Aducanumab was approved via the accelerated pathway for treatment o
- Advances in Preventive Treatment of Migraine Continuehttps://practicalneurology.com/news/advances-in-preventive-treatment-of-migraine-continue/2469756/At the Scottsdale Headache Symposium, the latest pharmacologic treatments for prevention of episodic migraine were reviewed. The focus remained on pharmacologic therapies that inhibit or block the effects of calcitonin gene-related peptide (CGRP) and its receptor—the first preventive treatm